NAD⁺ precursor — enters cells via ENT transporters, phosphorylated to NMN by NRK1/2, then adenylated to NAD⁺ by NMNAT. Smaller than NMN (no phosphate) so better cell entry. Raises whole-blood NAD⁺ ~40–60% at 300 mg/d in published RCTs.
Half-Life (t½)
PO: 1h
Dosing Guidelines
PO: Typical 167 mg (Range: 100–300 mg)
Target Organ Systems
endocrine
musculoskeletal
Interactions
NMN (synergistic): Parallel NAD⁺ precursor; converge at NAD⁺ pool.
TMG (synergistic): Methyl-donor support for downstream NNMT methylation.
NAD⁺ (synergistic): Upstream precursor via NRK1/2 → NMN → NAD⁺.